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ABSTRACT
The metabolic state of the body can be a major determinant of bone health. We used a Mendelian randomization approach to
identify metabolites causally associated with bonemass to better understand the biological mechanisms of osteoporosis. We tested
bone phenotypes (femoral neck, total hip, and lumbar spine bone mineral density [BMD]) for association with 280 fasting blood
metabolites in 6055 women from TwinsUK cohort with genomewide genotyping scans. Causal associations between metabolites
and bone phenotypes were further assessed in a bidirectional Mendelian randomization study using genetic markers/scores as
instrumental variables. Signiﬁcant associations were replicated in 624 participants from the Hong Kong Osteoporosis Study (HKOS).
Fifteen metabolites showed direct associations with bone phenotypes after adjusting for covariates and multiple testing. Using
genetic instruments, four of these metabolites were found to be causally associated with hip or spine BMD. These included
androsterone sulfate, epiandrosterone sulfate, 5alpha-androstan-3beta17beta-diol disulfate (encoded by CYP3A5), and 4-androsten-
3beta17beta-diol disulfate (encoded by SULT2A1). In the HKOS population, all four metabolites showed signiﬁcant associations with
hip and spine BMD in the expected directions. No causal reverse association between BMD and any of themetabolites were found. In
the ﬁrst metabolome-genomewide Mendelian randomization study of human bone mineral density, we identiﬁed four novel
biomarkers causally associated with BMD. Our ﬁndings reveal novel biological pathways involved in the pathogenesis of
osteoporosis. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
KEY WORDS: METABOLOMICS; GENOMEWIDE ASSOCIATION STUDIES; MENDELIAN RANDOMIZATION; INSTRUMENTAL VARIABLES ANALYSIS;
BONE MINERAL DENSITY; OSTEOPOROSIS
Introduction
It is now established that genetic factors, environmentalfactors, and their interactions play a major role in osteoporosis
pathogenesis.(1) In addition, metabolic pathways play an impor-
tant role in age-related bone loss. Several circulating proteins
and metabolites are known biomarkers of bone turnover and
can help to identify the state of bone formation/resorption for
diagnostic or therapeutic purposes.(2) Observation of bone loss
accompanying several endocrinological, inﬂammatory, gastro-
intestinal, renal, and nutritional disorders,(3) often known as
secondary osteoporosis, also suggests that the metabolic state
of the body can be a major determinant of bone health.
Identiﬁcation of metabolites that are causally associated with
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reduced bone mass will increase our power to understand the
biological mechanisms of osteoporosis and to develop drug
targets for bone health.
Causality, however, cannot be inferred from observational
studies,(4) and randomized controlled trials are considered the
gold standard for establishing causal relationships. Recently,
Mendelian randomization (MR), an instrumental variable analy-
sis method, has been proposed as an alternative for establishing
causal relationships.(5) For inference of causal relationships
between an exposure (eg, a metabolite) and an outcome (eg,
bone mineral density [BMD]), a susceptibility variant (or the
genetic risk score) of the exposure is used as instrument. The
association of this instrument with the exposure is not affected
by any confounding factors (because the genetic sequence is
randomly assigned during conception), and it is associated with
the outcome only via its effects on the exposure.(6) MR has been
successful in inferring causality for several clinically important
traits(7) and for elucidating the complex etiology of common
disease.(8)
In this study, we used MR on a genome-metabolome-wide
scale. We ﬁrst looked for circulating metabolites associated with
bone density measures in a large cohort of twins with
metabolomic data. We then searched for the genetic markers
of those metabolites associated with BMD and used them as
instrumental variables to identify metabolites causally associ-
ated with bone health. For evaluating bidirectional effects, we
also used genetic risk scores for BMD measures as instrumental
variables. Lastly, we replicated our ﬁndings in an independent
cohort from Hong Kong.
Materials and Methods
The ﬂowchart of the study design is presented in Fig. 1.
Discovery cohort
The TwinsUK study, started in 1992, is a nationwide registry of
volunteer twins in the UK, with about 12,000 registered twins
(83% female predominantlymiddle-agedandolder).(9) The cohort
has extensive demographic, physiological, behavioral, and
lifestyle data available and is one of themost deeply phenotyped
andgenotyped cohorts in theworld. The study has been an active
partner of many large collaborative projects including Genetic
Factors for Osteoporosis (GEFOS) consortium.(10) The study has
been approved by St. Thomas’ Hospital Research Ethics Commit-
tee, and all twins have provided informed written consent.
Dual-energy X-ray absorptiometry (DXA) was used tomeasure
BMD at the lumbar spine (L1 to L4) and hip regions (Hologic
Discovery W devices, Hologic, Bedford, MA, USA). In total, 15,491
hip and spine DXA scans were performed in 7056 twins
during 17 years of follow-up.(11) All BMD measurements were
performed by trained technicians using a standardized protocol
of measurement. Daily quality-control scans were performed
using the spine phantom. For this study, we included all female
Fig. 1. Flow chart of the study.
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twins with metabolomic data and at least one BMD measure-
ment in hip/spine regions. DXA scans from the same date of
blood sampling for metabolomic analysis were used in 4650
twins, and BMDmeasurements from the closest date (if multiple
measurements) were selected for 453 twins without DXA in the
same date of blood sampling (up to 2 years differences were
allowed). This resulted in a study population of 5103 participants
(mean age 53.8 13.8 years).
Replication cohort
The Hong Kong Osteoporosis Study (HKOS) is a prospective
longitudinal cohort study of osteoporosis and fracture that
started in 1995. The cohort participants were community-
dwelling Southern Chinese men and women of Han descent
recruited from public road shows and health fairs held in various
districts of Hong Kong from 1995 to 2010.(12) A total of 9449
participants were recruited. In 2015, a full-scale in-person follow-
up study was conducted. DXA has been used tomeasure BMD at
the lumbar spine (L1 to L4) and hip regions (Hologic QDR
2000plus and 4500plus systems at baseline; Hologic Discovery A
and Horizon A at follow-up study). All BMD measurements were
performed by trained technicians using a standardized protocol.
Daily quality-control scans were performed using the spine
phantom and across the DXA machines to make sure of
consistent measurements.
Metabolomic profiling
Non-targeted metabolite detection and quantiﬁcation was
conducted by the metabolomics provider (Metabolon, Inc.,
Durham, NC, USA) on fasting blood samples of 6055 twins, as
previously described.(13) This platform incorporates two sepa-
rate ultra-high-performance liquid chromatography/tandem
mass spectrometry injections and one gas chromatography/
mass spectrometry injection per sample, and can detect
metabolites in the range of low nanograms per milliliter.(14) In
previous studies, the platform ﬁndings have been shown to be
highly stable(15) and reproducible (with median relative
standard deviation of 5% for internal standards added to
samples before mass spectrometry).(14) The same metabolomic
proﬁling was also performed on 340 and 291 serum samples
from different participants in the HKOS baseline and follow-up
studies, respectively. Blood samples were taken in the same day
of DXA scans for all patients.
In this study, we analyzed 280 structurally named biochem-
icals (known metabolites) categorized into the following broad
categories: amino acids, lipids, carbohydrates, vitamins, nucleo-
tides, peptides, xenobiotics, and steroids.
Genomewide association study (GWAS)
Genomewide genotyping was performed for 5710 participants
of the TwinsUK study using two chips (HumanHap300 BeadChip
and HumanHap610 QuadChip, Illumina, San Diego, CA, USA).
The genotype data have been imputed (using HapMap II
reference panel containing 2.5 million autosomal single-
nucleotide polymorphisms [SNPs]) and used in several interna-
tional consortia for different phenotypes.(10) In this study, we
performed genomewide association studies (GWAS) for all
metabolites including those signiﬁcantly associated with bone
phenotypes.(16) The software MERLIN was used to account for
twin structure. Results from the largest GWAS meta-analysis for
BMD measures(17) were used to calculate genetic risk scores
(GRS) for hip and spine BMD.
Statistical analysis
All models were built using Stata (version 14, StataCorp LLC,
College Station, TX, USA) and SIMCA software (version 13,
Umetrics, Umeå, Sweden). For quality control of metabolomic
data, we had to consider that mass spectrometry was performed
over several days for the cohort samples, and measured
concentrations were variable according to run days. We,
therefore, normalized the metabolite data by dividing each
metabolite concentration by itsmedian in the respective run day
and then inverse normalized the data because the metabolite
concentrations were not normally distributed. Moreover, to
avoid spurious false-positive associations due to small sample
size, we excluded metabolomic traits with more than 20%
missing values. We imputed individual metabolites not detected
in a sample using the minimum measures in their run day. The
same QC procedure was performed in HKOS.
Association analysis in TwinsUK
To assess the predictive power of combined metabolites,
we used orthogonal-partial least squares (O-PLS) regression. We
used a sevenfold cross-validation technique to validate the
O-PLSmodels.(18) Goodness-of-ﬁt measures were reported for all
models in training (coefﬁcient of variation labeled as R2) and
cross-validation (coefﬁcient of variation labeled as Q2) sets. For
univariate metabolite-BMD trait associations, we used mixed-
effects random-intercept models considering family relatedness
and zygosity as random effects variables, and age, height,
weight, and duration of hormone-replacement therapy (HRT; as
a continuous variable in units of years) as confounders.
Mendelian randomization analysis
For the metabolomic GWAS analysis, we only considered
metabolites passing the Bonferroni corrected threshold of
p< 1.79 104 (0.05 divided by 280, for the number of known
metabolites) for association with at least one of the BMD
phenotypes. Genomic loci passing a stringent threshold for
association with thesemetabolites (p< 1 1010 for the sentinel
SNP in a locus) as well as hip and spine GRS scores were
considered for the bidirectional instrumental variable analysis.(16)
In the direct metabolite-to-BMD analysis, metabolite levels were
used as endogenous variables; age, height, weight, and duration
of HRT were included as exogenous variables; and allele
frequency (additive model) was used as the instrument.
Bidirectional Mendelian randomization (MR)(19,20) also investi-
gates for any evidence of reverse causality (ie, BMD causally
inﬂuencing metabolite levels) by use of GRS scores as the
instrument and BMD measures as the endogenous variables for
metabolite level outcomes. We used the generalized method of
moments (GMM) with cluster-robust heteroskedastic-consistent
variance estimates.(21) Under-, weak-, and over-identiﬁcation
limitations were checked. Bootstrap resampling of the data
(10,000 repetitions) was used for the calculation of robust
estimates of standard errors from instrumental variables analysis.
Replication in the HKOS
Multivariable robust regression models were used to evaluate
metabolites found to be causally associated with BMD in the
TwinsUK cohort. We reported all the association between these
metabolites and BMD, adjusting for age, sex, height, and weight
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from the same visit as DXA and metabolic measurements. HRT
users were excluded in the metabolomic study. Analyses were
conducted separately in the baseline and follow-up studies and
then meta-analyzed using inverse variance method.
Results
The demographic characteristics of the study populations are
presented in Table 1.
Metabolomic signature of osteoporosis
Principal components analysis (PCA) showed 38 signiﬁcant
components in our panel with the cumulative R2 of 55% in the
training set and 35.5% in the cross-validation set (Q2). O-PLS
modeling conﬁrmed one component as predictive and two as
orthogonal for prediction of BMD in different regions. Models
showed higher predictive power of metabolites for total hip
BMD (R2¼ 21.5% and Q2¼ 17.7%) and femoral neck BMD
(R2¼ 18.9% and Q2¼ 15.6%) compared with lumbar spine
(R2¼ 15.0% and Q2¼ 10.5%). A scatter plot of observed versus
predicted values for total hip BMD based on the O-PLS model is
presented in Fig. 2.
Metabolite associations
Applying stringent multiple testing correction for metabolite-
BMD associations, three metabolites were associated with
femoral neck BMD, 13 metabolites with total hip BMD, and 10
metabolites with lumbar spine BMD (15 metabolites in total;
Table 2). Two metabolites (prolyl-hydroxyproline and caffeine)
showed signiﬁcant associations with all skeletal sites measured.
Several sulfated adrenal androgens (including androsterone,
epiandrosterone, dehydroisoandrosterone, 5alpha-androstan-
3beta,17beta-diol, and two metabolomic features related to
4-androsten-3beta,17beta-diol) were associated with total hip
or spine BMD. Three metabolites related to the metabolic
pathways of valine, leucine, and isoleucine metabolism
(4-methyl-2-oxopentanoate, alpha-hydroxyisovalerate, and
3-methyl-2-oxovalerate) and one related to tryptophan metab-
olism (C-glycosyltryptophan) were also associated with BMD.
Mendelian randomization
Results of the bidirectional MR analyses for all metabolites are
shown in the Supplemental Material. In the direct instrumental
variables analysis, four sulfated adrenal androgen levels
(androsterone sulfate, epiandrosterone sulfate, 5alpha-andro-
stan-3beta,17beta-diol disulfate, and 4-androsten-3beta,17-
beta-diol disulfate 1) showed causal associations with BMD
traits (Table 3). We could not see any evidence for a reverse
relationship (ie, BMD causing anymetabolite level changes). The
ﬁrst three metabolites were instrumented on SNP rs4646450
(chromosome 7q22.1), an intron variant of the CYP3A5 gene
(cytochrome P450, family 3, subfamily A, polypeptide 5). This
gene encodes a member of the cytochrome P450 superfamily of
enzymes. These enzymes catalyze many reactions involved in
drug metabolism and synthesis of cholesterol, steroids (eg,
testosterone, progesterone, and androstenedione), and other
lipids. The other metabolite was instrumented on SNP
rs16981893 (chromosome 19q13.33). This SNP is downstream
of the SULT2A1 gene (sulfotransferase family, cytosolic, 2A,
dehydroepiandrosterone-preferring, member 1). Sulfotransfer-
ases aid in the metabolism and excretion of drugs and
endogenous compounds. The product of SULT2A1 catalyzes
the sulfation of steroids and bile acids in the liver and adrenal
glands.
Replication in the HKOS
To further evaluate the generalizability of these ﬁndings, we
replicated these causally associated metabolites in the HKOS. All
four metabolites were signiﬁcantly replicated in the HKOS
(Table 4). The variance explained (adjusted R2) by these
metabolites were 2.7% and 1.2% for BMD at the total hip and
lumbar spine, respectively, after adjustment for age, sex, height,
and weight. The corresponding numbers for the TwinsUK
population were 0.83% and 0.80%, respectively.
Discussion
To the best of our knowledge, this is the ﬁrst study that uses
two levels of “omics” data to detect the causal associations
between blood-circulating metabolites and BMD variation. We
conﬁrmed the causal role of adrenal-secreted sulfated steroids in
osteoporosis and identiﬁed two novel genetic loci (CYP3A5 and
SULT2A1) to be important in the regulation of metabolites
causing osteoporosis. Successful replication of the causally
Table 1. Demographic Characteristics of the Study Populations
(Mean [SD])
TwinsUK HKOS
No. 6055 624
Male/female 434/5621 112/512
Age (years) 53.45 (14.00) 52.05 (14.25)
Body mass index (kg/m2) 26.07 (4.91) 22.83 (3.84)
Height (m) 1.62 (0.07) 1.58 (0.08)
Weight (kg) 69.24 (13.78) 56.98 (11.26)
Femoral neck BMD (mg/cm2) 786.98 (129.42) 710.62 (167.51)
Total hip BMD (mg/cm2) 926.12 (133.67) 815.12 (176.04)
Lumbar spine BMD (mg/cm2) 985.58 (152.75) 919.03 (203.01)
SD¼ standard deviation; HKOS¼Hong Kong Osteoporosis Study;
BMD¼bone mineral density.
Fig. 2. Scatter plot of observed versus predicted total hip bone mineral
density (BMD) values based on orthogonally ﬁltered partial least
square (O-PLS) model with 280 metabolites among 4937 participants.
RMSEe¼ root mean square error of the estimation (the ﬁt) for training
sample; RMSEcv¼ root mean square error for cross-validation sample.
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associated metabolites in another ethnic group also demon-
strated a high generalizability of our ﬁndings.
The contribution of metabolites into BMD variation is not yet
established. Previous metabolomic studies have mainly focused
on low BMD associations using low-resolution techniques
instead of looking into BMD variations across the whole range
in large population cohorts.(22,23) Using a high-throughput
metabolomic platform measuring 280 known metabolites in a
large population, we showed that circulating metabolites
explained about 35% to 55% of BMD variation in all skeletal
sites measured. This can have important clinical applications
because circulating metabolite levels can be used as markers of
bone health, predictors of risk of osteoporotic fractures, and
markers of treatment effects or potential intervention targets
(diet and medications).
Using the MR approach, we found that sulfated adrenal
androgen plays a causal role in bone metabolism. These
metabolites are related to androgen metabolism, and androgen
has long been known as an anabolic agent in bone metabolism.
However, whether the elevated levels of these metabolites
represent the higher levels of endogenous androgen in the
participants or contribute individually to bone metabolism is
unknown and needs further assessment. Our previous study
showed that one of these metabolites, epiandrosterone sulfate,
was signiﬁcantly associated with chronic widespread musculo-
skeletal pain.(24) The SNP rs4646450 has shown signiﬁcant
association with femoral neck BMD in the GEFOS consortium
meta-analysis.(17) Importantly, all the causally associated
metabolites in the TwinsUK study showed direct association
with BMD in the HKOS population, and collectively explained
2.7% variance of BMD variation at the total hip. This raises hope
for potential feasible metabolic interventions, either diagnostic
or therapeutic, in clinical management of osteoporosis.
It is important to note that we cannot exclude a potential
causal association of themetabolites associatedwith BMD in our
study but not included in the MR analysis. This is mainly related
to the lack of reliable genetic instruments for running MR
analyses for these metabolites. For instance, prolyl-hydroxypro-
line showed signiﬁcant association with BMD in all three
measurement sites, but we could not ﬁnd any genetic variant for
it in our GWAS. This metabolite is a known marker of bone
collagen degradation, and its urinary excretion has been
previously linked to postmenopausal osteoporosis.(2,25) Caffeine
also showed direct associations with BMD variation in our study,
but this should be interpreted cautiously because the levels of
this xenobiotic may only reﬂect short-term exposure to coffee in
participants and not be related to the risk of osteoporosis
associatedwith long-term coffee intake. The effect of caffeine on
bone has been controversial throughout literature.(26)
Our study shows that combining two sources of “omics”
studies (genomics and metabolomics) would be beneﬁcial in
uncovering the pathogenesis of osteoporosis and other
complex health conditions. Although genetic factors are well-
known markers of osteoporosis, combining 63 susceptibility
variants in the largest genomewide meta-analysis only ex-
plained 5.8% of the variance of femoral neck BMD variation.(17)
Although these genetic studies can bring several important
clinical applications,(1) the genetic variations per se are not
modiﬁable and so the ﬁndings cannot be directly translated into
clinical practice. Using these genetic markers as instruments for
Table 2. Metabolites Signiﬁcantly Associated With BMD Phenotypes in TwinsUK Population
Trait Metabolite Beta (SE) p Value
Femoral neck BMD Prolyl-hydroxyproline –11.0 (1.75) 3.8 1010
Caffeine 6.8 (1.66) 3.8 105
C-glycosyltryptophan –7.1 (1.85) 1.2 104
Total hip BMD Prolyl-hydroxyproline –14.57 (1.76) 2.3 1016
4-androsten-3beta,17beta-diol disulfate 1 13.48 (2.07) 9.6 1011
Dehydroisoandrosterone sulfate (DHEAS) 12.39 (2.02) 1.0 109
4-methyl-2-oxopentanoate 9.79 (1.79) 4.9 108
C-glycosyltryptophan –9.8 (1.87) 1.8 107
Epiandrosterone sulfate 9.4 (1.85) 3.9 107
Androsterone sulfate 8.94 (1.85) 1.4 106
4-androsten-3beta,17beta-diol disulfate 2 10.37 (2.18) 2.1 106
5alpha-androstan-3beta,17beta-diol disulfate 9.27 (2.07) 8.0 106
Caffeine 7.21 (1.75) 3.8 105
Pipecolate 6.81 (1.68) 5.1 105
Alpha-hydroxyisovalerate 6.99 (1.77) 8.2 105
3-methyl-2-oxovalerate 6.98 (1.8) 1.0 104
Lumbar spine BMD Prolyl-hydroxyproline –16.97 (2.2) 2.0 1014
4-androsten-3beta,17beta-diol disulfate 1 15.36 (2.61) 4.6 109
Creatinine 10.25 (2.21) 3.6 106
5alpha-androstan-3beta,17beta-diol disulfate 11.87 (2.56) 3.8 106
5alpha-pregnan-3beta,20alpha-diol disulfate 11.38 (2.56) 9.5 106
Dehydroisoandrosterone sulfate (DHEAS) 11.02 (2.49) 9.9 106
Alpha-hydroxyisovalerate 9.24 (2.22) 3.2 105
Pipecolate 8.62 (2.16) 6.6 105
Caffeine 8.39 (2.16) 1.0 104
4-methyl-2-oxopentanoate 8.4 (2.18) 1.2 104
BMD¼bone mineral density; SE¼ standard error.
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discovery of causally associated metabolites can reveal more
insight on the pathological pathways to diseases and potential
interventions.
Our study has several strengths. This is the ﬁrst study that used
two levels of “omics” data to detect the causal associations
between blood-circulating metabolites and BMD variation.
The results were further replicated in another ethnic group,
highlighting the high reliability and generalizability of the
ﬁndings. Both TwinsUK and HKOS are well-characterized cohorts
for osteoporosis. The metabolomic proﬁling in TwinsUK and
HKOS were performed on the same platform by the same
provider with a highly stringent quality control, making the
metabolomic data comparable between cohorts.
Our study has some limitations. There is a potential for
horizontal pleiotropy in our study (ie, variants used as instru-
ments can directly inﬂuence other metabolites, which then
inﬂuence BMD). We could not employ new extensions of the MR
method (namely multivariable MR(27) and MR Egger regres-
sion)(28) because of power limitations. Metabolites were
measured in a relative manner and so their absolute concen-
trations cannot be inferred. Moreover, the difference in levels of
metabolites between British and Chinese participants could not
be assessed (given separate normalized values in each
population). Patients receiving HRT were excluded from the
metabolomics and genomics studies in the HKOS cohort at the
design stage. This may cause some differences in the target
populations of the cohorts, although use of HRT is not common
in the Chinese population. False-negative causal associations are
quite likely attributable to lack of validated genetic instruments
for several metabolites. Future collaborative studies with larger
sample sizes are required to evaluate the role of other
BMD-associated metabolites in bone metabolism.
Our ﬁndings have important clinical implications. Currently,
there is a crisis in the treatment of osteoporosis worldwide.(29)
Patients are generally afraid of initiating or using anti-
osteoporosis treatments because of the fear of severe but rare
side effects. Thus, the development of novel therapeutic agents
for improving bone health is important. The causal metabolic
pathway identiﬁed in this study may provide insight on
therapeutic agent development. Moreover, the associated
metabolites may be used as a biomarker of osteoporosis or
potentially as a dietary supplement to improve BMD. Follow-up
studies are now underway to evaluate the importance of these
ﬁndings.
In conclusion, circulating metabolites measured using a
high-throughput metabolomic technique explained more than
one-third of the variance of BMD in a large female population.
Fifteen unique metabolites showed direct association with BMD
variation, four of which were found to be causally associated
using genetic instruments. The direct association between these
metabolites and BMD were replicated in an independent
Chinese population. Combining both genomic and metabolo-
mic data provided a unique platform for elucidating the role
of new pathways in the pathogenesis and diagnosis of
osteoporosis.
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